New Pancreatic Cancer Immunotherapy Approach to Be Shared
A new research presentation will explore how targeting KRAS may help immunotherapy better fight pancreatic cancer cells.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe recent advancements in targeted cancer therapy will improve treatment success rates in your area?
At the 2026 Society for Immunotherapy of Cancer annual meeting, researcher Paarth Dodhiawala will present findings on how inhibiting the KRAS oncoprotein may help sensitize pancreatic cancer to NK cell immunotherapy. The presentation is scheduled for November 6, 2026, in Phoenix, AZ.
Why it matters
Pancreatic cancer remains a difficult-to-treat malignancy, and exploring new methods to improve the efficacy of immune-based therapies is a significant area of ongoing oncological research. This presentation highlights a novel approach using KRAS inhibition to potentially enhance natural killer cell activity.
The findings will be shared as abstract number 655 during the Society for Immunotherapy of Cancer 2026 Annual Meeting. Whether this combination of KRAS inhibition and NK cell therapy will yield clinical success remains an area of ongoing investigation.
The players
Paarth Dodhiawala
A researcher at the University of Minnesota Medical School who is leading the presentation.
GT Biopharma
A biopharmaceutical company focused on developing therapies that leverage NK cell biology.
Society for Immunotherapy of Cancer
A professional medical society that promotes research and education in cancer immunotherapy.
The details
The research focuses on the KRAS oncoprotein, a frequent driver of tumor growth in pancreatic cancer. By inhibiting this protein, the researchers aim to make cancer cells more susceptible to the body's natural killer (NK) cells. GT Biopharma, which holds an exclusive worldwide license for the TriKE technology used in this work, will showcase these results during a session on combination therapies.
Timeline
The SITC 2026 Annual Meeting runs from November 4 to November 8, 2026.
The presentation takes place on November 6, 2026, from 3:05 PM to 3:20 PM Mountain Time.
Health Landscape
Targeting the KRAS oncoprotein has long been a challenge in oncology, with new research now seeking to combine these efforts with immunotherapy. This presentation fits into the broader evolution of using multi-modal treatments to enhance immune responses against aggressive cancers.
This study is a research-stage presentation and does not represent a change in current clinical treatment guidelines. Patients interested in how emerging immunotherapy combinations may apply to pancreatic cancer care should discuss the latest clinical trial options with their oncologist.
The takeaway
This presentation explores whether targeting the KRAS protein can improve immune-based treatments for pancreatic cancer. As this is preliminary research, patients should consult their medical team to understand if clinical trials currently offer experimental immunotherapy options for their specific diagnosis.
Further reading
For more on the current state of oncology research, visit Cancer.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe recent advancements in targeted cancer therapy will improve treatment success rates in your area?
